Is there any therapeutic value for the use of histone deacetylase inhibitors for chronic pain?

被引：21
|
作者：
Wang, Wei [1 ]
Cui, Shan-shan [2 ]
Lu, Rui [1 ]
Zhang, Hui [1 ]
机构：
[1] Fourth Mil Med Univ, Sch Stomatol, Dept Anesthesiol, State Key Lab Mil Stomatol, Xian 710032, Peoples R China
[2] Wuhan Univ, Zhongnan Hosp, Dept Anesthesiol, East Lake Rd, Wuhan 430071, Peoples R China
来源：
BRAIN RESEARCH BULLETIN | 2016年 / 125卷
基金：
中国国家自然科学基金;
关键词：
Chronic pain; Histone deacetylases; Epigenetic; Inhibitors; CHRONIC CONSTRICTION INJURY; PERIPHERAL-NERVE INJURY; OPIOID-INDUCED HYPERALGESIA; CPG-BINDING PROTEIN-2; NEUROPATHIC PAIN; VALPROIC ACID; EPIGENETIC REGULATION; HDAC INHIBITORS; SPINAL-CORD; PERSISTENT PAIN;
D O I：
10.1016/j.brainresbull.2016.04.010
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Chronic pain is a complex clinical condition that reduces the quality of life for billions of people. In recent years, the role of epigenetic modulation in the control of long-term neuronal plasticity has attracted the attention of pain researchers. The epigenetic mechanisms include covalent modifications of DNA and/or histone proteins. Mounting evidence suggests that the activity of histone deacetylases (HDACs) and levels of histone acetylation are dynamic and that these enzymes modulate pain-related synaptic plasticity. Therefore, HDACs play essential roles in chronic pain development and maintenance. In this mini review, we will discuss the role of HDACs in the pathogenesis of chronic pain and will consider the therapeutic value of HDAC inhibitors in treating chronic pain. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码：44 / 52
页数：9
相关论文
共 50 条
  • [1] Histone deacetylase inhibitors:: mechanism of action and therapeutic use in cancer
    Martinez-Iglesias, Olaia
    Ruiz-Llorente, Lidia
    Sanchez-Martinez, Ruth
    Garcia, Laura
    Zambrano, Alberto
    Aranda, Ana
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (07): : 395 - 398
  • [2] Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer
    Olaia Martínez-Iglesias
    Lidia Ruiz-Llorente
    Ruth Sánchez-Martínez
    Laura García
    Alberto Zambrano
    Ana Aranda
    Clinical and Translational Oncology, 2008, 10 : 395 - 398
  • [3] Therapeutic applications of histone deacetylase inhibitors in sarcoma
    Tang, Fan
    Choy, Edwin
    Tu, Chongqi
    Hornicek, Francis
    Duan, Zhenfeng
    CANCER TREATMENT REVIEWS, 2017, 59 : 33 - 45
  • [4] Rationale for the Use of Histone Deacetylase Inhibitors as a Dual Therapeutic Modality in Multiple Sclerosis
    Gray, Steven G.
    Dangond, Fernando
    EPIGENETICS, 2006, 1 (02) : 67 - 75
  • [5] Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective
    Tsilimigras, Diamantis, I
    Ntanasis-Stathopoulos, Ioannis
    Moris, Demetrios
    Spartalis, Eleftherios
    Pawlik, Timothy M.
    SURGICAL ONCOLOGY-OXFORD, 2018, 27 (04): : 611 - 618
  • [6] Therapeutic effects of histone deacetylase inhibitors on kidney disease
    Chun, Pusoon
    ARCHIVES OF PHARMACAL RESEARCH, 2018, 41 (02) : 162 - 183
  • [7] Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer
    Feng, Wan
    Zhang, Bin
    Cai, Dawei
    Zou, Xiaoping
    CANCER LETTERS, 2014, 347 (02) : 183 - 190
  • [8] Histone deacetylase inhibitors: Emerging anticancer therapeutic agents?
    Kristeleit, Rebecca
    Fong, Peter
    Aherne, G. Wynne
    de Bono, Johann
    CLINICAL LUNG CANCER, 2005, 7 : S19 - S30
  • [9] Therapeutic potential of histone deacetylase inhibitors in human liposarcomas
    Muhlenberg, Thomas
    Pedeutour, Florence
    Fletcher, Jonathan A.
    Schuler, Martin
    Bauer, Sebastian
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [10] Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?
    Ziemka-Nalecz, Malgorzata
    Jaworska, Joanna
    Sypecka, Joanna
    Zalewska, Teresa
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2018, 77 (10): : 855 - 870
12345